Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
CME Group director Patrick W. Maloney reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Maloney now beneficially owns 4,098 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: $145,251.96
CME Group director Harold Eugene Ford Jr. reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Ford's direct beneficial ownership increased to 2,091 shares. The Form 4 filing indicates this was a standard director compensation grant, demonstrating ongoing alignment between board member and shareholder interests.
- Transaction Type: Stock Award (Code A)
- Role: Director (Non-Employee)
- Filing Type: Individual
- Ownership: Direct
CME Group director Elizabeth A. Cook reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 532 shares of Class A Common Stock at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Cook's beneficial ownership includes:
- 18,771 shares held indirectly through a trust
- 20 shares held indirectly through a joint account
The Form 4 filing was signed by Jenelle Chalmers on behalf of Elizabeth A. Cook on June 26, 2025. This transaction represents a standard director compensation grant and demonstrates continued insider investment in the company.
CME Group director Timothy S. Bitsberger reported an insider transaction on Form 4 filed June 28, 2025, disclosing activity from June 25, 2025. Key details:
- Acquired 532 shares of Class A Common Stock at $273.03 per share
- Shares were granted through the CME Group Director Stock Plan
- Following the transaction, Bitsberger directly owns 11,121 shares
This transaction represents a standard director stock grant as part of CME Group's board compensation program. The filing was signed by Jenelle Chalmers on behalf of Bitsberger on June 26, 2025. No derivative securities were involved in this transaction.
CME Group director Rahael Seifu reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted through the CME Group Director Stock Plan.
Following this transaction, Seifu now beneficially owns 4,094 shares directly. The filing indicates this was a planned compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Plan-Based)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Patrick J. Mulchrone reported insider trading activity on June 25, 2025. Key details of the transaction include:
- Acquired 532 shares of Class A Common Stock at $273.03 per share through the CME Group Director Stock Plan
- Following the transaction, Mulchrone directly owns 28,485 shares
- Additionally holds 25,000 shares indirectly through spouse
The Form 4 filing indicates this was a planned acquisition under the company's director compensation program rather than an open market transaction. The filing was submitted by Jenelle Chalmers on behalf of Mulchrone on June 26, 2025, within the required reporting timeframe.
CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lockett now beneficially owns 3,640 shares directly. The filing indicates this was a planned stock grant as part of director compensation rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: Approximately $145,252
This insider transaction represents routine director compensation and does not indicate any unusual trading patterns or significant changes in ownership structure.
CME Group director Deborah J. Lucas reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lucas now beneficially owns 3,888 shares directly. The filing indicates this was a routine director stock grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Bryan T. Durkin reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Durkin now beneficially owns 47,207 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Value of Transaction: $145,251.96
CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Type: Stock Grant (Code A)
- Reporting Person Role: Director
- Ownership Form: Direct
- Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye